Phase I Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel and Bevacizumab in Patients With Previously Untreated Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma

Inclusion Criteria:

- Histology diagnoses epithelial ovarian, primary peritoneal, or fallopian tube(Stage
II, III or IV)either optimal or suboptimal after initial surgery.

- All patients must have had appropriate surgery for ovarian, peritoneal, or
fallopian tube carcinoma with tissue available for histologic evaluation

- Histologic epithelial cell types are eligible: serous adenocarcinoma,
endometrioid adenocarcinoma, mucinous adenocarinoma, undifferentiated carcinoma,
clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell
carcinoma, malignant brenner tumor, adenocarcinoma NOS.

- GOG(Gynecologic Oncology Group)performance status of 0,1,2

- Entered within 12 weeks of most recent surgery performed for diagnosis.

- Patients must have adequate bone marrow function, renal function,hepatic function,
neurologic function, blood coagulation parameters within normal limits

- Sign approved consent form.

Exclusion Criteria:

- Patients who have received prior treatment other than initial surgery

- Patients who have received prior radiotherapy to any portion of their abdominal
cavity or pelvis

- Patients with acute hepatitis or active infection

- Patients with active bleeding

- Patients with unstable angina

- Patients with history of invasive malignancies with the exception of nonmelanoma skin
cancer and localized breast cancer.

- Patients who have received any target therapy or hormonal therapy for management of
their ovarian cancer.

- Patients with synchronous primary endometrial cancer.

- Patients with epithelial tumors of low malignant potential

- Serious non healing wound, ulcer or bone fracture.

- Patients with history or evidence of CNS(central nervous system disease)

- Patients under 18 years old.

- Patients who have received prior therapy with anti-VEGF(vascular endothelial growth
factor)

drug, bevacizumab

- Patients who have a history of allergic reaction to polysorbate 80.